Intra-Cellular Therapies, Inc. (ITCI) Just Recorded A Sigfniciant Increase

February 15, 2018 - By Dolores Ford

Investors sentiment increased to 2.77 in 2017 Q3. Its up 1.91, from 0.86 in 2017Q2. It improved, as 9 investors sold Intra-Cellular Therapies, Inc. shares while 21 reduced holdings. 45 funds opened positions while 38 raised stakes. 39.74 million shares or 30.25% more from 30.51 million shares in 2017Q2 were reported.
Ameritas Investment Prtn accumulated 2,964 shares or 0% of the stock. Deerfield Mgmt Co invested in 0.08% or 118,116 shares. Hillhouse Mngmt reported 1.00M shares. Weiss Multi has 0.06% invested in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) for 104,700 shares. Msd Ptnrs L P invested in 25,000 shares or 0.01% of the stock. Utah-based Wasatch Advsrs has invested 0.42% in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Credit Suisse Ag invested 0% in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Trexquant Lp owns 0.13% invested in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) for 32,176 shares. Voya Investment Management Limited Company reported 16,911 shares. Price T Rowe Assocs Md invested in 16,536 shares. Legal General Public Ltd Liability holds 0% or 16,942 shares. Natl Bank Of America De owns 805,834 shares. Moreover, Alpine Woods Cap Investors Lc has 0.07% invested in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) for 91,544 shares. Endurance Wealth Mngmt holds 325 shares or 0% of its portfolio. Rhenman Partners Asset Ab invested in 1.18M shares or 2.38% of the stock.

Since September 29, 2017, it had 3 buys, and 9 insider sales for $10.92 million activity. 258,065 shares valued at $4.00M were bought by ALAFI CAPITAL CO LLC on Monday, October 2. Shares for $459,765 were sold by Halstead Michael. The insider Vanover Kimberly E. sold $20,583. 1,115 shares valued at $17,394 were sold by Davis Robert E on Wednesday, January 3. Mates Sharon sold $192,270 worth of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) on Wednesday, January 3. The insider Hineline Lawrence J. sold $82,725.

The stock of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) is a huge mover today! The stock increased 4.01% or $0.77 during the last trading session, reaching $19.96. About 597,421 shares traded or 36.99% up from the average. Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) has declined 68.76% since February 15, 2017 and is downtrending. It has underperformed by 85.46% the S&P500.
The move comes after 9 months positive chart setup for the $1.09 billion company. It was reported on Feb, 15 by We have $21.76 PT which if reached, will make NASDAQ:ITCI worth $98.01M more.

Analysts await Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) to report earnings on March, 7. They expect $-0.51 earnings per share, up 20.31 % or $0.13 from last year’s $-0.64 per share. After $-0.53 actual earnings per share reported by Intra-Cellular Therapies, Inc. for the previous quarter, Wall Street now forecasts -3.77 % EPS growth.

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Ratings Coverage

Among 11 analysts covering Intra-Cellular Therapies (NASDAQ:ITCI), 10 have Buy rating, 0 Sell and 1 Hold. Therefore 91% are positive. Intra-Cellular Therapies had 36 analyst reports since August 6, 2015 according to SRatingsIntel. On Wednesday, August 9 the stock rating was maintained by Piper Jaffray with “Hold”. Guggenheim maintained Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) on Thursday, September 17 with “Buy” rating. The company was maintained on Wednesday, August 9 by Cowen & Co. The rating was maintained by JMP Securities with “Market Outperform” on Wednesday, March 9. As per Wednesday, August 9, the company rating was maintained by Cantor Fitzgerald. The company was maintained on Wednesday, August 23 by Cowen & Co. The stock of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) earned “Buy” rating by Cantor Fitzgerald on Monday, September 25. The stock has “Market Outperform” rating by JMP Securities on Thursday, August 24. Cantor Fitzgerald maintained Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) rating on Thursday, September 7. Cantor Fitzgerald has “Buy” rating and $29.0 target. The stock has “Neutral” rating by Ladenburg Thalmann on Tuesday, May 2.

More notable recent Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) news were published by: which released: “Intra-Cellular Therapies: Positive FDA Response Leads To A Rebound In Share Price” on September 01, 2017, also with their article: “Intra-Cellular Therapies Announces Positive Regulatory Update On Schizophrenia …” published on August 23, 2017, published: “Intra-Cellular Therapies to Present at Upcoming Investor Conferences” on February 07, 2018. More interesting news about Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) were released by: and their article: “Why Intra-Cellular Therapies Is Plunging” published on May 01, 2017 as well as‘s news article titled: “Intra-Cellular Therapies Reports Third Quarter 2017 Financial Results and …” with publication date: November 08, 2017.

Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The company has market cap of $1.09 billion. The firm is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, depression, and other neuropsychiatric and neurological disorders. It currently has negative earnings. Lumateperone, a molecule, is in Phase III clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.